A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program

While U.S. Sen. Kamala Harris (D-Calif.) has not been one of the most high profile senators on 340B issues, the Democratic vice presidential candidate has not been shy to express her support for the program and challenge the Trump administration’s policies on 340B. Harris, who began serving in the Senate in January 2017, was one of 11 Democratic senators who signed a letter in late 2017 blasting the administration’s foot dragging on a 340B program final regulation that would increase oversight of pharmaceutical manufacturers. Democratic presidential candidate Joe Biden introduced Harris as his running mate yesterday.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

A Closer Look at Democratic VP Choice Harris’s Positions on the 340B Program

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga